Led · Series A · Jul 2022

NutriSense is a metabolic health technology company that pairs data from continuous glucose monitoring technology with personalized one-on-one dietitian coaching. The platform provides real-time glucose feedback and actionable insights to help members personalize nutrition and drive behavior change. The company says its offering delivers an authentic human experience to guide members on their health journey. NutriSense launched in 2019 and has grown to over 120 teammates globally and added thousands of subscription members. The company intends to use new capital to grow its operational team and expand outreach to new members. NutriSense positions itself as democratizing access to personalized health monitoring for consumers seeking to optimize metabolic wellness.

Led · Series C · Aug 2017

Colorescience develops and markets mineral-based skincare and sun-protection products that are backed by clinical validation and deliver broad-spectrum protection. Its line is positioned as premium and science-driven, targeting both consumers and professional practitioners. The company has built multi-channel distribution that spans dermatology offices, med-spas, direct-to-consumer sales, and major e-commerce platforms. Management emphasizes strong consumer advocacy and differentiation through science and innovation. With new backing, the brand plans to expand awareness, deepen penetration in existing channels, and broaden its product portfolio while maintaining its clinical focus. Although financial figures were not disclosed, the company’s momentum and differentiated product set were highlighted as key investment drivers.

Participated · Series B · Apr 2017

Onkos Surgical is a medical device company focused on solutions for complex orthopaedic procedures, including adult and pediatric cases involving bone loss from tumor, trauma, or revision of failed implants. Its product portfolio includes virtual surgical planning, 3D anatomic modeling and printing, implant design, workflow optimization, and NanoCept, an antibacterial coating for orthopaedic implants. NanoCept was granted the first-ever FDA De Novo authorization for an antibacterial coating used on orthopaedic implants in April 2024 and has demonstrated up to a 99.999% kill rate in standardized in‑vitro testing, along with reported safety and biocompatibility. Onkos says more than 350 leading U.S. academic medical institutions use its products for complex revision and tumor orthopaedic cases. The company plans to accelerate manufacturing and commercialization of NanoCept to expand its footprint in a stated $3 billion market. Onkos is backed by investors including 1315 Capital, Canaan Partners, and SV Health Investors. Onkos Surgical provides surgical solutions for musculoskeletal oncology and complex orthopaedic procedures, offering a personalized Precision Orthopaedics approach. The company uses virtual surgical planning, 3D modeling and printing, implant design, and workflow optimization to improve patient outcomes. More than 350 medical institutions in the U.S. use Onkos’ solutions. It raised $15M in a Series C to accelerate its research and development pipeline, expand its commercial footprint, and evolve manufacturing capabilities. The backers were part of an existing investor syndicate and were not disclosed. Led by Co‑Founder and CEO Patrick Treacy and based in Parsippany, NJ, Onkos focuses on surgeon-driven, patient-inspired approaches to address implant loosening, soft tissue failures, and infection. Onkos Surgical develops surgical oncology devices and implants, most recently launching the GenVie Magnesium Bone Scaffold earlier this year. The GenVie product is a magnesium-based bone void filler with osteoconductive properties and high compression strength intended to promote bone repair and regeneration. It is designed for surgically created osseous defects or defects resulting from traumatic injury. The company has pursued additional funding, filing an SEC Form D for an equity offering. To date it has sold approximately $7.57 million of a $12 million offering, with 11 investors participating. The offering is intended to be completed within one year and to augment the company’s prior $17.6 million Series B closed in 2017. Onkos Surgical develops surgical oncology implants, instruments and related biologic products. Its core product line includes the ELEOSTM Limb Salvage System, a modular system indicated for procedures requiring radical resection and replacement of the distal femur, proximal femur, proximal tibia or total femur. The company also creates personalized implant, instrument and anatomic model designs to aid surgeons during operative procedures. Onkos provides a suite of biologic products with applications specific to musculoskeletal oncology. Founded in 2015 by Patrick Treacy, the company intends to use new funds to expand its sales, marketing and R&D platforms. It is based in Pasipanny, NJ. Onkos Surgical is a surgical oncology company founded in 2015 that develops and plans to commercialize personalized medicine platforms and advanced 3D‑printed surgical solutions. The company intends to leverage 3D printing to create customized implants and platforms for segmental oncologic reconstructions. It has partnered with MicroPort Orthopedics to gain access to a core portfolio of segmental prostheses and established a distribution partner in China to support market access. Onkos was founded by Patrick Treacy, Antony Koblish and 1315 Capital and is based in Parsippany, New Jersey. Financially, the company has closed a Series A round (amount undisclosed) to advance its development and commercialization plans. No operating metrics were disclosed in the article.